Novartis lifted its full-year steering after first-quarter revenue and gross sales rose and beat consensus expectations, boosted by robust gross sales of key medication.
Novartis lifted its full-year steering after first-quarter revenue and gross sales rose and beat consensus expectations, boosted by robust gross sales of key medication.